{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:17:13Z","timestamp":1783808233760,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.pupt.2015.06.004","type":"journal-article","created":{"date-parts":[[2015,6,23]],"date-time":"2015-06-23T16:12:11Z","timestamp":1435075931000},"page":"47-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy of erdosteine 900 versus 600\u00a0mg\/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial"],"prefix":"10.1016","volume":"33","author":[{"given":"R.W.","family":"Dal Negro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2015.06.004_bib1","series-title":"Preventing Chronic Diseases: a Vital Investment","author":"World Health Organization","year":"2005"},{"key":"10.1016\/j.pupt.2015.06.004_bib2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, Update 2013, www.goldcopd.org (accessed March 2015)."},{"key":"10.1016\/j.pupt.2015.06.004_bib3","series-title":"European Lung White Book: Huddersfield","author":"European Respiratory Society","year":"2003"},{"key":"10.1016\/j.pupt.2015.06.004_bib4","series-title":"Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Diseases","author":"National Heart, Lung, and Blood Institute","year":"2012"},{"key":"10.1016\/j.pupt.2015.06.004_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/CEOR.S77504","article-title":"Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update","volume":"7","author":"Dal Negro","year":"2015","journal-title":"Clin. Outcomes Res."},{"key":"10.1016\/j.pupt.2015.06.004_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(07)61382-8","article-title":"COPD exacerbations: defining their cause and prevention","volume":"370","author":"Wedzicha","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2015.06.004_bib7","series-title":"The Global Burden of Disease: a Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020","year":"1996"},{"key":"10.1016\/j.pupt.2015.06.004_bib8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1183\/09031936.00092506","article-title":"Inflammatory changes, recovery and recurrence at COPD exacerbation","volume":"29","author":"Perera","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.06.004_bib9","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1164\/ajrccm.150.6.7952628","article-title":"Airway eosinophilia in chronic bronchitis during exacerbations","volume":"150","author":"Saetta","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2015.06.004_bib10","series-title":"Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care","author":"NICE Guidelines (CG101)","year":"2010"},{"key":"10.1016\/j.pupt.2015.06.004_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/thx.2008.099127","article-title":"Recent advances in exacerbations of COPD","volume":"63","author":"Seemungal","year":"2008","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.pupt.2015.06.004_bib12","first-page":"238","article-title":"Erdosteine protection against cigarette smoking-induced functional antiprotease deficiency in human bronchiolo-alveolar structures","volume":"27","author":"Vagliasindi","year":"1989","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"issue":"5","key":"10.1016\/j.pupt.2015.06.004_bib13","first-page":"235","article-title":"Erdosteine protection from cigarette smoke-induced loss of alpha 1-antitrypsin activity in rat lungs","volume":"27","author":"Biagi","year":"1989","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.pupt.2015.06.004_bib14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.pupt.2007.07.004","article-title":"Changes in blood ROS, e-NO and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD","volume":"21","author":"Dal Negro","year":"2008","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pupt.2015.06.004_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pupt.2009.10.002","article-title":"The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data","volume":"23","author":"Cazzola","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"Suppl.\u00a057","key":"10.1016\/j.pupt.2015.06.004_bib16","first-page":"P3393","article-title":"Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD","volume":"42","author":"Moretti","year":"2013","journal-title":"ERJ"},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1517\/17425250902814790","article-title":"Erdosteine: its relevance in COPD treatment","volume":"5","author":"Moretti","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.pupt.2015.06.004_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1513\/pats.200701-003FM","article-title":"Exacerbations of chronic obstructive pulmonary disease","volume":"4","author":"Anzueto","year":"2007","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"6","key":"10.1016\/j.pupt.2015.06.004_bib19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00109906","article-title":"Exacerbations of chronic obstructive pulmonary disease","volume":"29","author":"Celli","year":"2007","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2015.06.004_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"176","author":"Rabe","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.pupt.2015.06.004_bib21","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"committee members ATS\/ERS task force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib22","first-page":"205","article-title":"Future therapeutic treatment of COPD: struggle between oxidants and cytokines","volume":"2","author":"de Boer","year":"2007","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"7","key":"10.1016\/j.pupt.2015.06.004_bib23","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/thx.53.7.601","article-title":"Role of transcription factors in inflammatory lung diseases","volume":"53","author":"Rahman","year":"1998","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib24","first-page":"CD001287","article-title":"Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease","volume":"19","author":"Poole","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.pupt.2015.06.004_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1513\/pats.201102-016RM","article-title":"Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease","volume":"8","author":"Han","year":"2011","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S2213-2600(13)70286-8","article-title":"Twice daily N-acetylcysteine 600\u00a0mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial","volume":"2","author":"Zheng","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S2213-2600(13)70294-7","article-title":"N-acetylcysteine in COPD may be beneficial, but for whom?","volume":"2","author":"Cazzola","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.pupt.2015.06.004_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1753465808096109","article-title":"Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD","volume":"2","author":"Dal Negro","year":"2008","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"3","key":"10.1016\/j.pupt.2015.06.004_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/17476348.1.3.307","article-title":"Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease","volume":"1","author":"Moretti","year":"2007","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.pupt.2015.06.004_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.5414\/CPP49041","article-title":"Erdosteine affects eicosanoid production in COPD","volume":"49","author":"Dal Negro","year":"2011","journal-title":"Int. J. Clin. Pharmacol. Ther."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T16:19:19Z","timestamp":1566922759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553915000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":30,"alternative-id":["S1094553915000693"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2015.06.004","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of erdosteine 900 versus 600\u00a0mg\/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2015.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}